STAA
Staar Surgical along with its subsidiaries designs, develops, manufactures and sells implantable lenses and delivery systems for the eye. The Company develops, produces, and markets intraocular lenses.
STAAR Surgical Company (STAA) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Value (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | D (1.5) | D+ (1.8) | B (3.3) | C+ (2.6) | A+ (5.0) | C+ (2.8) |
| 2026-11-08 | D (1.4) | C- (2.0) | B (3.3) | C+ (2.7) | A+ (5.0) | B- (2.9) |
| 2026-11-01 | D+ (1.8) | B (3.2) | B (3.4) | C+ (2.6) | A+ (5.0) | B (3.2) |
| 2026-10-25 | D+ (1.8) | B (3.2) | B (3.3) | C (2.2) | A+ (5.0) | B- (3.1) |
| 2026-10-18 | C- (1.9) | B (3.2) | B (3.3) | C (2.2) | A+ (5.0) | B- (3.1) |